ProCE Banner Activity

What to Know About the New Approval for Abemaciclib in Patients With Early Breast Cancer

Clinical Thought

Hear expert perspective from Laura M. Spring, MD, on how she will integrate adjuvant abemaciclib into clinical practice.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Released: November 29, 2021

Expiration: November 28, 2022

No longer available for credit.

Share

Faculty

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Supporters

Supported by an educational grant from

Lilly

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD, has disclosed that she has received funds for research support from Merck and Tesaro and consulting fees from Avrobio and Novartis.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.

Jill A. Sakai,

Contributing Editor

Jill Sakai, PhD, has no relevant conflicts of interest to report.